US2003125349A1PendingUtilityA1

Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients

47
Assignee: SOLVAY PHARM GMBHPriority: Jul 26, 2000Filed: Jan 22, 2003Published: Jul 3, 2003
Est. expiryJul 26, 2020(expired)· nominal 20-yr term from priority
Inventors:Werner CautreelsClaus SteinbornHeinz KrauseSteven CarasEgbertus Hendrikus Evert BiesheuvelAlbertus Hermannus Dirk Plekkenpol
A61K 31/437A61K 31/439A61K 31/496A61K 31/4184A61K 31/4985A61K 31/538A61K 31/4178
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of inhibiting preparations for the treatment and/or prophylaxis of irritable bowel syndrome (=IBS) in a non-obstipative male patient, said method comprising administering to said patient a pharmaceutical composition comprising an effective IBS inhibiting amount of cilansetron or a pharmacologically acceptable acid addition salt thereof or a solvate thereof.  
     
     
         2 . A method according to  claim 1 , wherein said pharmaceutical composition comprises cilansetron hydrochloride.  
     
     
         3 . A method according to  claim 1 , wherein said pharmaceutical composition comprises cilansetron hydrochloride monohydrate.  
     
     
         4 . A method of treating a human patient suffering from irritable bowel syndrome (=IBS), said method comprising administering a pharmaceutical composition comprising at least one 5HT 3 -receptor antagonist to said patient three times a day.  
     
     
         5 . A method according to  claim 4 , wherein said at least one 5HT 3 -receptor antagonist is administered in a dose of from 1 mg to 16 mg.  
     
     
         6 . A method according to  claim 4 , wherein the three times daily administration of said pharmaceutical composition takes place after morning, mid-day and evening meals, respectively.  
     
     
         7 . A method according to  claim 4 , wherein said 5HT 3 -receptor antagonist comprises at least one active substance selected from the group consisting of alosetron, azasetron, dolasetron, granisetron, indisetron, itasetron, lerisetron, ondansetron, ramosetron, tropisetron, and (R)-Zacopride.  
     
     
         8 . A method according to  claim 4 , wherein said 5HT 3 -receptor antagonist comprises cilansetron or a pharmacologically acceptable acid addition salt thereof or a solvates thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.